Second-line CML drugs evoke faster, better front-line remissions

Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication, according to two studies published online by the New England Journal of Medicine.

Read the whole article on Physorg

More from Physorg